We have a team of editors dedicted to bringing you breaking news from within the medical sector. All our articles are completely unbiased and based on the industry as a whole. Please filter the news by your preferred profession below.
Apply to us in seconds, let us find you the perfect job.
Register as an PharmacistRefer a friend and earn £200 after they finish 4 weeks work!
Refer an Pharmacist
Thursday 30th June 2011
A new type of therapeutics known as recombinant attenuated Salmonella vaccines (RASV) look set to combat many fatal infectious diseases.
The list of illnesses the vaccines could potentially target include hepatitis B, tuberculosis, cholera, typhoid fever, AIDS and pneumonia.
Researchers at the Biodesign Institutue at Arizona State University have now developed a technique which could make these vaccines not only safer, but more effective.
Existing vaccines are difficult to bring into the developing world for a number of reasons including that heat stabilisation and needle injection are needed - usually impractical for the mass innoculation required in these areas. Additionally, high costs of existing vaccines mean that those who really need them often do not have access.
The findings, published in the Journal of Immunology, revealed that one of the most promising strategies for new vaccine development is to use a pathogen as a vessel to deliver key antigens from the pathogen researchers wish to vaccinate against.
A research team aimed to retain the immunogenicity of an anti-pneumonia RASV while reducing or erasing unwanted side effects which sometimes accompany immunisation with the vaccine, such as fever and intestinal distress.
After being injected with the new Salmonella strain, mice were seen to produce a strong antibody response to pneumococcal surface protein A (PspA), which is responsible for generating antibodies to pneumonia. Therefore, the mice exhibited a greatly improved immunity to wild-type Streptococcus pneumonia compared to those who were inoculated with the Salmonella vaccine without the PspA agent.
Chief scientist Dr Roy Curtiss explained: "Orally-administered RASVs stimulate all three branches of the immune system stimulating mucosal, humoral, and cellular immunity that will be protective, in this case, against a majority of pneumococcal strains causing disease."
Written by Angela Newbury

We have a new Pharmacy Technician Job available in the Norfolk area. We are looking for a motivated Pharmacy Technician...
Full infoLocum Pharmacy Technician required for an immediate start within a Prison setting for an ongoing assignment. We are currently...
Full infoACT Technician required for immediate startMediplacements are currently recruiting for an ACT Pharmacy Technician to work...
Full infoCall 0845 230 6666
Fax 0845 230 6677
The Placement Group JustPhysio JustOT
Mediplacements is a member of The Placement Group.
Mediplacements partners with JustPhysio and JustOT